3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neuroendocrine Tumors
5
Carcinoid Tumor
3
Serotonin Syndrome
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors in Lung
1
Neoplasm Metastasis
1
Gigantism
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Flushing
1
Endocrine Tumors
1
Diarrhea
1
Acromegaly
1
Interventions
Prednisone
112
Docetaxel
87
Leuprolide
79
enzalutamide
72
Abiraterone Acetate
67
bicalutamide
53
Goserelin
50
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
42
Radiotherapy
39
abiraterone
28
Magnetic Resonance Spectroscopy
27
Gonadotropin-Releasing Hormone
24
gallium 68 PSMA-11
23
apalutamide
22
Androgen Antagonists
22
luprolide acetate gel depot
21
sipuleucel-T
20
Radiosurgery
20
Triptorelin Pamoate
18
cabazitaxel
17
cabozantinib
16
Radiotherapy, Intensity-Modulated
16
Flutamide
16
pembrolizumab
15
radium Ra 223 dichloride
14
Prednisolone
14
Nivolumab
14
Dutasteride
14
Dexamethasone
14
Radiation
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Prostatic Neoplasms
×
lanreotide
×
Clear all
NCT01313273
2019-11-22
POSEIDON
Ipsen
Phase 3
Terminated
3 enrolled
4 charts